PARG1 Antibody - BSA Free

Western Blot: PARG1 Antibody [NBP1-05989] - Whole cell lysate from HeLa, 293T, and mouse NIH3T3 cells. PARG1 was also immunoprecipitated by rabbit anti-PARG1 antibody NBP1-05988.

(A) Probability of interaction of Rho GTPase activating protein 29 (ARHGAP29) with AKT1, SIRT1, PTPN13, CDC42, MAGEA11, and RHOD. In silico analyses were carried out using the GIANT web server (Genome-wide Integrated Analysis of gene Networks in Tissues, provided by HumanBase, //hb.flatironinstitute.org/, last accessed on 26 July 2019). A value of 0.1 was chosen as a minimum confidence interval to investigate interactions. The maximum number of genes considered was seven. The color of the connecting lines between interaction partners reflects possible interactions from 0 (no interaction) to 1 (high probability of interaction). The expression of AKT1 and the pAKT1/AKT1 ratio in MCF-7-EMT (B), T-47D-EMT (C), and HCC1806 (D) breast cancer cells after knock-down of ARHGAP29 expression are shown. Breast cancer cells were transiently transfected with ARHGAP29-specific siRNA or non-targeting control siRNA (control). The expression of AKT1 was determined using Western blot analysis and normalized to GAPDH expression using at least three biological and technical replicates. The pAKT1/AKT1 ratio was analyzed as the quotient of pAKT1 versus AKT1 expression. Representative blots for ARHGAP29, AKT1 and pAKT1 are shown. Mean +/- SEM values are given. Significance was determined with the help of unpaired t-tests; (***) p < 0.001; (**) p < 0.01; (*) p < 0.05. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/33291460), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

(A) Probability of interaction of Rho GTPase activating protein 29 (ARHGAP29) with AKT1, SIRT1, PTPN13, CDC42, MAGEA11, and RHOD. In silico analyses were carried out using the GIANT web server (Genome-wide Integrated Analysis of gene Networks in Tissues, provided by HumanBase, //hb.flatironinstitute.org/, last accessed on 26 July 2019). A value of 0.1 was chosen as a minimum confidence interval to investigate interactions. The maximum number of genes considered was seven. The color of the connecting lines between interaction partners reflects possible interactions from 0 (no interaction) to 1 (high probability of interaction). The expression of AKT1 and the pAKT1/AKT1 ratio in MCF-7-EMT (B), T-47D-EMT (C), and HCC1806 (D) breast cancer cells after knock-down of ARHGAP29 expression are shown. Breast cancer cells were transiently transfected with ARHGAP29-specific siRNA or non-targeting control siRNA (control). The expression of AKT1 was determined using Western blot analysis and normalized to GAPDH expression using at least three biological and technical replicates. The pAKT1/AKT1 ratio was analyzed as the quotient of pAKT1 versus AKT1 expression. Representative blots for ARHGAP29, AKT1 and pAKT1 are shown. Mean +/- SEM values are given. Significance was determined with the help of unpaired t-tests; (***) p < 0.001; (**) p < 0.01; (*) p < 0.05. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/33291460), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

(A) Probability of interaction of Rho GTPase activating protein 29 (ARHGAP29) with AKT1, SIRT1, PTPN13, CDC42, MAGEA11, and RHOD. In silico analyses were carried out using the GIANT web server (Genome-wide Integrated Analysis of gene Networks in Tissues, provided by HumanBase, //hb.flatironinstitute.org/, last accessed on 26 July 2019). A value of 0.1 was chosen as a minimum confidence interval to investigate interactions. The maximum number of genes considered was seven. The color of the connecting lines between interaction partners reflects possible interactions from 0 (no interaction) to 1 (high probability of interaction). The expression of AKT1 and the pAKT1/AKT1 ratio in MCF-7-EMT (B), T-47D-EMT (C), and HCC1806 (D) breast cancer cells after knock-down of ARHGAP29 expression are shown. Breast cancer cells were transiently transfected with ARHGAP29-specific siRNA or non-targeting control siRNA (control). The expression of AKT1 was determined using Western blot analysis and normalized to GAPDH expression using at least three biological and technical replicates. The pAKT1/AKT1 ratio was analyzed as the quotient of pAKT1 versus AKT1 expression. Representative blots for ARHGAP29, AKT1 and pAKT1 are shown. Mean +/- SEM values are given. Significance was determined with the help of unpaired t-tests; (***) p < 0.001; (**) p < 0.01; (*) p < 0.05. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/33291460), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

• Reactivity: Hu, Mu
• Applications: WB, ICC/IF, IHC, IP
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 1.0 mg/ml

PARG1 Antibody - BSA Free Summary

• Immunogen: The immunogen recognized by this antibody maps to a region between residue 1211 and 1261 of human PTPL1-associated RhoGAP 1 (NP_004806.3).
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: ARHGAP29
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry/ Immunofluorescence 1:10-1:500
  • Immunohistochemistry 1:10-1:500
  • Immunoprecipitation 2-5 ug/mg lysate
  • Western Blot 1:2000-1:10000
• Application Notes: ICC/IF, IHC reactivity reported in scientific literature (PMID: 23008150). Western blot of lysates performed using standard western blot reagents and 4-8% SDS-PAGE.
• Control:

  PARG1 Overexpression Lysate

Packaging, Storage & Formulations

• Storage: Store at 4C. Do not freeze.
• Buffer: Tris-Citrate/Phosphate (pH 7.0 - 8.0)
• Preservative: 0.09% Sodium Azide
• Concentration: 1.0 mg/ml
• Purity: Immunogen affinity purified

Alternate Names for PARG1 Antibody - BSA Free

• PARG1PTPL1-associated RhoGAP 1 (PARG1)
• PTPL1-associated RhoGAP protein 1
• Rho GTPase activating protein 29
• rho GTPase-activating protein 29
• Rho-type GTPase-activating protein 29
• RP11-255E17.1

Background

PARG1 (PTPL1-associated RhoGAP protein 1) is a GTPase-activating protein (GAP) for Rho and Rap2. PARG1 has recently been identified as a candidate tumor suppressor in mantle-cell lymphoma. Alternative names for PARG1 include Rho GTPase-activating protein 29 and ARHGAP29.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for PARG1 Antibody (NBP1-05989)(13)

Publications using NBP1-05989

• Tröster B, Kappelmann-Fenzl M, Bosserhoff A et al. Emerging role of ARHGAP29 in melanoma cell phenotype switching. Molecular oncology 2025-09-04 [PMID: 40906537]
• Rhea L, Reeb T, Adelizzi E et Al. ARHGAP29 promotes keratinocyte proliferation and migration in vitro and is dispensable for in vivo wound healing Dev Dyn 2024-11-19 [PMID: 39560169]
• MAIKE KANSY, KATHARINA WERT, KATHARINA KOLB, JULIA GALLWAS, CARSTEN GRÜNDKER ARHGAP29 Is Involved in Increased Invasiveness of Tamoxifen-resistant Breast Cancer Cells and its Expression Levels Correlate With Clinical Tumor Parameters of Breast Cancer Patients Cancer Genomics & Proteomics 2024-07-03 [PMID: 38944420]
• Reeb T, Rhea L, Adelizzi E et al. ARHGAP29 is required for keratinocyte proliferation and migration bioRxiv : the preprint server for biology 2023-02-01 [PMID: 36778214] (WB, Human)
• Li MJ, Shi JY, Zhang BH et al. Targeted re-sequencing on 1p22 among non-syndromic orofacial clefts from Han Chinese population Frontiers in genetics 2022-08-17 [PMID: 36061182] (IHC-P, WB, Human)
• Xu Q, Duan H, Gan L et al. MicroRNA-1291 promotes endometrial fibrosis by regulating the ArhGAP29-RhoA/ROCK1 signaling pathway in a murine model Mol Med Rep 2017-08-10 [PMID: 28849001] (IF/IHC, Mouse)
• Paul BJ, Palmer K, Sharp JC et al. ARHGAP29 Mutation Is Associated with Abnormal Oral Epithelial Adhesions J. Dent. Res. 2017-08-01 [PMID: 28817352] (WB, Mouse)
• Post A, Pannekoek WJ, Ponsioen B et al. Rap1 spatially controls ArhGAP29 to inhibit Rho signaling during endothelial barrier regulation. Mol. Cell. Biol. 2015-05-11 [PMID: 25963656] (ICC/IF, Human)
• Biggs LC, Naridze RL, Demali KA et al. Interferon regulatory factor 6 regulates keratinocyte migration. J. Cell. Sci. 2014-04-28 [PMID: 24777480] (WB, ICC/IF, Mouse)
• Post A, Pannekoek WJ, Ross SH et al. Rasip1 mediates Rap1 regulation of Rho in endothelial barrier function through ArhGAP29. Proc Natl Acad Sci U S A 2013-07-09 [PMID: 23798437] (WB, Human)
• Leslie EJ, Mansilla MA, Biggs LC et al. Expression and mutation analyses implicate ARHGAP29 as the etiologic gene for the cleft lip with or without cleft palate locus identified by genome-wide association on chromosome 1p22 Birth Defects Res A Clin Mol Teratol 2012-11-01 [PMID: 23008150] (IF/IHC, ICC/IF, Mouse)
• Leinhos L Myofibroblast differentiation in hypoxia: a novel role for ArhGAP29 Thesis (WB)
• Kolb K, Hellinger J, Kansy M et al. Influence of ARHGAP29 on the Invasion of Mesenchymal-Transformed Breast Cancer Cells Cells 2020-12-05 [PMID: 33291460] (WB, Human)

Bioinformatics

• Gene Symbol: ARHGAP29
• Entrez:
  • 9411(Human)
  • 214137(Mouse)
• Uniprot:
  • Q52LW3(Human)